SINTX Technologies Inc

SINTX Technologies Inc(SINT)股票分析

$1.560

-0.058 (-3.70%)收盤時

Loading chart…
最高
1.640
開盤
1.640
成交量加權均價
1.58
成交量
41.03K
市值
3.17M
最低
1.550
成交金額
64.96K
企業價值/稅息折舊攤銷前利潤(TTM)
-0.31

SINTX Technologies, Inc. is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. It is engaged in the research, development, and manufacturing of silicon nitride. Its core business includes biomedical applications and antipathogenic applications. It has been focused on medical grade silicon nitride. Spinal implants made from its silicon nitride have been implanted in humans. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Its composition of silicon nitride antipathogenic powder may enable manufacturing surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. It manufactures advanced ceramic powders and components in its manufacturing facilities based in Salt Lake City, Utah.

sintx.com

AI 分析 of SINTX Technologies Inc (SINT)

賣出

SINTX Technologies Inc is not a good buy right now due to its very low RSI of 23.718, indicating oversold conditions, and a significant year-to-date decline of 58.73%. The stock is currently trading at $1.56, which is only 5.2% above its 52-week low of $1.40, suggesting limited upside potential. Additionally, the company has reported substantial net losses, with a net income of -$3,632,000 in Q2 2026, raising concerns about its financial stability. The main risk is its high debt-to-equity ratio of 11.73% in Q1 2026, indicating potential liquidity issues.

估值指標

SINTX Technologies Inc(SINT)目前預期本益比為 0.00,5 年平均預期本益比為 -19.40。

預期本益比

合理
5 年均值 P/E
-19.40
目前P/E
0.00
高估
59.35
低估
-98.14

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-0.32
目前EV/EBITDA
-0.31
高估
0.29
低估
-0.94

預期股價營收比

合理
5 年均值 P/S
4.14
目前P/S
2.03
高估
8.10
低估
0.19

Alphio AI 對 SINT 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%SINT

$2.63

情境價格

基

基準

基準 · 50%SINT

$1.91

情境價格

悲

悲觀

悲觀 · 25%SINT

$1.46

情境價格

事件時間軸

2026-11-05 (ET)

17:30:00

SINTX Technologies Reports Q3 Revenue of $2.19M

2026-10-01 (ET)

09:30:00

Sintx Technologies Reports $2.2M Revenue for Q3

2026-08-13 (ET)

06:30:00

Selling Stockholders Plan to Sell 1.27M Shares of Common Stock

2026-06-25 (ET)

06:30:00

Sintx Technologies Files to Sell 5.82M Shares of Common Stock

2026-06-22 (ET)

10:00:00

Sintx Technologies Secures Over $3.2M in Orders

資訊

SINT 常見問題 —— 由 Alphio AI 解答

SINTX Technologies, Inc. is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. It is engaged in the research, development, and manufacturing of silicon nitride. Its core business includes biomedical applications and antipathogenic applications. It has been focused on medical grade silicon nitride. Spinal implants made from its silicon nitride have been implanted in humans. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Its composition of silicon nitride antipathogenic powder may enable manufacturing surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. It manufactures advanced ceramic powders and components in its manufacturing facilities based in Salt Lake City, Utah. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

SINTX Technologies Inc is not a good buy right now due to its very low RSI of 23.718, indicating oversold conditions, and a significant year-to-date decline of 58.73%. The stock is currently trading at $1.56, which is only 5.2% above its 52-week low of $1.40, suggesting limited upside potential. Additionally, the company has reported substantial net losses, with a net income of -$3,632,000 in Q2 2026, raising concerns about its financial stability. The main risk is its high debt-to-equity ratio of 11.73% in Q1 2026, indicating potential liquidity issues.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易